SCHEMBL17469380

SCHEMBL17469380

C[C@@H](O)[C@H](NC(=O)[C@H]1CCCN1)C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 1/20 0.46
CTSC P53634 5/20 0.42
PRCP P42785 2/20 0.41
NOS2 P35228 2/20 0.40
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
DDOST P39656 1/20 0.38
CALCRL Q16602 1/20 0.37
CTSK P43235 1/20 0.36
KCNH2 Q12809 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
TLR2 O60603 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19138319 1.00 DPP7 (0.46) DPP7CTSCPRCPNOS2NOS3
SCHEMBL17469367 1.00 DPP7 (0.46) DPP7CTSCPRCPNOS2NOS3
SCHEMBL19258205 1.00 DPP7 (0.46) DPP7CTSCPRCPNOS2NOS3
Hydrochloric Acid SCHEMBL28600562 0.98 DPP7 (0.45) DPP7CTSCPRCPNOS2NOS3
Hydrochloric Acid SCHEMBL28600564 0.98 DPP7 (0.45) DPP7CTSCPRCPNOS2NOS3
Hydrochloric Acid SCHEMBL28600561 0.98 DPP7 (0.45) DPP7CTSCPRCPNOS2NOS3
SCHEMBL30866235 0.89 DPP7 (0.47) DPP7CTSCPRCPNOS2NOS3
SCHEMBL25728331 0.89 DPP7 (0.47) DPP7CTSCPRCPNOS2NOS3
SCHEMBL21955441 0.89 DPP7 (0.47) DPP7CTSCPRCPNOS2NOS3
SCHEMBL34461082 0.86 DPP7 (0.47) DPP7CTSCPRCPCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3916003-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME Naurex, Inc. (US) 2021-12-01 EP disclosed
EP-3916003-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME Naurex, Inc. (US) 2021-12-01 EP disclosed
EP-3171941-B1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2021-03-24 EP disclosed
EP-3171941-B1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2021-03-24 EP disclosed
US-20180258139-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2018-09-13 US disclosed
US-9994614-B2 N-methyl-D-aspartate receptor modulators and methods of making and using same NAUREX, INC. (US) 2018-06-12 US disclosed
US-9994614-B2 N-methyl-D-aspartate receptor modulators and methods of making and using same NAUREX, INC. (US) 2018-06-12 US disclosed
US-20170210779-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2017-07-27 US disclosed
US-20170210779-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX INC (US) 2017-07-27 US disclosed
WO-2016014982-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME NAUREX, INC. (US) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180258139-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME GRIN1, GRIN2A, GRIN3A DPP7 1257/4885CTSC 1977/4885PRCP 1950/4885
US-20170210779-A1 N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME GRIN1, GRIN2A, GRIN3A DPP7 1257/4885CTSC 1977/4885PRCP 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.